These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 23629506)

  • 1. Advances in the development of new tuberculosis drugs and treatment regimens.
    Zumla A; Nahid P; Cole ST
    Nat Rev Drug Discov; 2013 May; 12(5):388-404. PubMed ID: 23629506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.
    Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D
    Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
    Palomino JC; Martin A
    Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Tiberi S; Buchanan R; Caminero JA; Centis R; Arbex MA; Salazar M; Potter J; Migliori GB
    Presse Med; 2017 Mar; 46(2 Pt 2):e41-e51. PubMed ID: 28256383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuberculosis: current treatment, diagnostics, and newer antitubercular agents in clinical trials.
    Ahsan MJ; Ansari MY; Yasmin S; Jadav SS; Kumar P; Garg SK; Aseri A; Khalilullah H
    Infect Disord Drug Targets; 2015; 15(1):32-41. PubMed ID: 25246035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the treatment of tuberculosis.
    Motta I; Boeree M; Chesov D; Dheda K; Günther G; Horsburgh CR; Kherabi Y; Lange C; Lienhardt C; McIlleron HM; Paton NI; Stagg HR; Thwaites G; Udwadia Z; Van Crevel R; Velásquez GE; Wilkinson RJ; Guglielmetti L;
    Clin Microbiol Infect; 2024 Sep; 30(9):1107-1114. PubMed ID: 37482332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.
    Wallis RS; Maeurer M; Mwaba P; Chakaya J; Rustomjee R; Migliori GB; Marais B; Schito M; Churchyard G; Swaminathan S; Hoelscher M; Zumla A
    Lancet Infect Dis; 2016 Apr; 16(4):e34-46. PubMed ID: 27036358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pipeline of drugs for related diseases: tuberculosis.
    Dooley KE; Nuermberger EL; Diacon AH
    Curr Opin HIV AIDS; 2013 Nov; 8(6):579-85. PubMed ID: 24100880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host- Directed Therapies.
    Borah P; Deb PK; Venugopala KN; Al-Shar'i NA; Singh V; Deka S; Srivastava A; Tiwari V; Mailavaram RP
    Curr Top Med Chem; 2021; 21(6):547-570. PubMed ID: 33319660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive clinical trials in tuberculosis: applications, challenges and solutions.
    Davies GR; Phillips PP; Jaki T
    Int J Tuberc Lung Dis; 2015 Jun; 19(6):626-34. PubMed ID: 25946350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.
    Zumla AI; Gillespie SH; Hoelscher M; Philips PP; Cole ST; Abubakar I; McHugh TD; Schito M; Maeurer M; Nunn AJ
    Lancet Infect Dis; 2014 Apr; 14(4):327-40. PubMed ID: 24670627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).
    Lupien A; Vocat A; Foo CS; Blattes E; Gillon JY; Makarov V; Cole ST
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging drugs for active tuberculosis.
    Ginsberg AM
    Semin Respir Crit Care Med; 2008 Oct; 29(5):552-9. PubMed ID: 18810688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.